
Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
To own Ingevity, you need to believe the portfolio reshaping and cost focus can eventually turn current losses into more resilient earnings. The latest quarter’s swing to a US$84.6 million loss, alongside a full year net loss of US$167.1 million, keeps pressure on near term execution, but does not fundamentally change the main near term catalyst, which remains the company’s ability to stabilize margins in Advanced Polymer Technologies. The largest risk stays weaker demand in key industrial and automotive end markets.
The announcement that Ingevity will shrink its board from 11 to 9 members following the 2026 annual meeting is the most connected to this earnings release. It comes as the company absorbs continued APT challenges, tariff uncertainty and still modest EBITDA margin guidance for that segment. For investors focused on the margin improvement catalyst, this governance adjustment sits in the background while the real focus remains on how the business responds operationally to...
Read the full narrative on Ingevity (it's free!)
Ingevity's narrative projects $1.5 billion revenue and $412.8 million earnings by 2028.
Uncover how Ingevity's forecasts yield a $70.75 fair value, in line with its current price.
Two fair value estimates from the Simply Wall St Community span a wide range, from about US$70.75 up to roughly US$184.95 per share. You can weigh these views against the ongoing risk that tariff related pressures and weak global industrial demand keep Advanced Polymer Technologies margins stuck at the lower end of guidance.
Explore 2 other fair value estimates on Ingevity - why the stock might be worth over 2x more than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com